medigraphic.com
ISSN 0188-2198 (Impreso)

2017, Número 3

<< Anterior Siguiente >>

Rev Mex Cardiol 2017; 28 (3)


Predictores de la progresión de los trastornos metabólicos y la resistencia a la insulina en pacientes con hipertensión arterial y diabetes mellitus tipo 2

Bilivol OM, Bobronnikova LR, Al-Trawneh OV

Idioma: Ingles.
Referencias bibliográficas: 21
Paginas: 118-123
Archivo PDF: 183.44 Kb.


RESUMEN

Se analizaron los mecanismos de progresión de los trastornos metabólicos en pacientes con hipertensión arterial y diabetes mellitus tipo 2, de los cuales los más significativos son el estado de resistencia a la insulina, los trastornos del metabolismo de los carbohidratos, el desarrollo de dislipidemia aterogénica y la inflamación sistémica en correlación con el desequilibrio de las adipocitoquinas, lo que contribuye al alto riesgo cardiovascular.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Montecucco F, Pende A, Quercioli A, Mach F. Inflammation in the pathophysiology of essential hypertension. J Nephrol. 2011; 24: 23-34.

  2. Shimamoto K, Miura T, Nippon R. Metabolic syndrome. 2009; 67 (4): 771-776.

  3. Yamawaki H. Vascular effects of novel adipocytokines: focus on vascular contractility and inflammatory responses. Biol Pharm Bull. 2011; 34 (3): 307-310.

  4. Hackam DG, Khan NA, Hemmelgarn BR, Rabkin SW, Touyz RM, Campbell NR et al. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension. Can J Cardiol. 2010; 26 (5): 249-258.

  5. Emerging Risk Factors Collaboration1, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010; 375 (9733): 2215-2222.

  6. Pereira M, Lunet N, Azevedo A, Barros H. Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens. 2009; 27: 963-975.

  7. Fonseca VA. Defining and characterizing the progression of type 2 diabetes. Diabetes Care. 2009; 32 (2): 151-156.

  8. Aroor RA, Mandavia CH, Sowers JR. Insulin resistance and heart failure: molecular mechanisms. Heart Fail Clin. 2012; 8 (4): 609-617.

  9. Boudina S. Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord. 2010; 11: 31-39.

  10. Zhou J, Qin G. Adipocyte dysfunction and hypertension. Am J Cardiovasc Dis. 2012; 2 (2): 143-149.

  11. Mracek T, Gao D, Tzanavari T et al. Downregulation of zinc-α2-glycoprotein in adipose tissue and liver of obese ob/ob mice and by tumour necrosis factor-α in adipocytes. J Endocrinol. 2010; 204 (2): 165-172.

  12. Gong FY, Zhang SJ, Deng JY, Zhu HJ, Pan H, Li NS et al. Zinc-α2-glycoprotein is involved in regulation of body weight through inhibition of lipogenic enzymes in adipose tissue. Int J Obes (Lond). 2009; 33 (9): 1023-1030.

  13. Selva DM, Lecube A, Hernandez C, Baena JA, Fort JM, Simó R. Lower zinc- α2-glycoprotein production by adipose tissue and liver in obese patients unrelated to insulin resistance. J Clin Endocrinol Metab. 2009; 94 (11): 4499-4507.

  14. Byerley LO, Lee SH, Redmann S, Culberson C, Clemens M, Lively MO. Evidence for a novel serum factor distinct from zinc alpha-2 glycoprotein that promotes body fat loss early in the development of cachexia. Nutrition and Cancer. 2010; 62 (4): 484-494.

  15. Olofsson LE, Olsson B, Lystig T, Jacobson P, Jernås M, Sjöholm K et al. Preliminary report: Zn-alpha2-glycoprotein genotype and serum levels are associated with serum lipids. Metabolism: Clinical and Experimental. 2010; 59 (9): 1316-1318.

  16. Russell ST, Tisdale MJ. Studies on the antiobesity effect of zinc-α2-glycoprotein in the ob/ob mouse. Int J Obes (Lond). 2011; 35 (3): 345-354.

  17. Russell ST, Tisdale MJ. Studies on the anti-obesity activity of zinc-α2-glycoprotein in the rat. Int J Obesity. 2011; 35 (5): 658-665.

  18. Zhu HJ, Dong CX, Pan H, Ping XC, Li NS, Dai YF et al. Rs4215 SNP in zinc-α2- glycoprotein gene is associated with obesity in Chinese north Han population. Gene. 2012; 500 (2): 211-215.

  19. Stepan H, Philipp A, Roth I, Kralisch S, Jank A, Schaarschmidt W et al. Serum levels of the adipokine zinc-alpha2-glycoprotein are increased in preeclampsia. J Endocrinol Invest. 2012; 35: 562-565.

  20. Leal VO, Lobo JC, Stockler-Pinto MB, Farage NE, Abdalla DS, Leite M Jr et al. Is zinc- α2-glycoprotein a cardiovascular protective factor for patients undergoing hemodialysis? Clin Chim Acta. 2012; 413 (5-6): 616-619.

  21. Tedeschi S, Pilotti E, Parenti E, Vicini V, Coghi P, Montanari A et al. Serum adipokine zinc α2-glycoprotein and lipolysis in cachectic and noncachectic heart failure patients: relationship with neurohormonal and inflammatory biomarkers. Metabolism. 2012; 61 (1): 37-42.




2020     |     www.medigraphic.com